RNA NANOPARTICLES

Catalogued Products

  • RNA Nanoparticles for Targeting Study
    View
  • RNA Nanoparticles for miRNA17 Delivery Study
    View
  • RNA Nanoparticles for miRNA17 Delivery Study
    View
  • RNA Nanoparticles for miRNA17 Delivery Study
    View
  • RNA Nanoparticles for miRNA Delivery Study, scramble controls
    View
  • RNA Nanoparticles for siRNA Delivery Study
    View
  • RNA Nanoparticles for Bilipid Membrane Staining
    View

Customized Products

Custom Design: Select the ligand for targeting specific cancer cells and desired therapeutic modules (miRNA, anti-miRNA, siRNA or
chemical drug) for your research needs. We can prepare the required RNA nanoparticles with high quality and in large scale for

General Design of RNA Nanoparticles

  • SCAFFOLD

    pRNA-3WJ 2’-Fluoro RNA is highly thermodynamically and enzymatically stable and remain intact at ultra-low concentrations in circulating blood. It is an ideal scaffold for drug delivery. RNA scaffolds with various shapes and sizes are also available.

  • TARGETING LIGAND

    he nucleic acid based aptamers and small chemical ligand can be conjugated to one end of pRNA-3WJ scaffold to achieve specific targeting. The high thermodynamic stability of pRNA-3WJ ensures the correct folding of aptamer sequences and its function.

  • THERAPEUTIC MODULE

    Small nucleic acid based therapeutic candidates, such as miRNA, anti-miRNA, siRNA, CpG DNA immune modulators, and chemical drugs can be easily conjugated to one end of pRNA-3WJ scaffold, with authentic functionalities.

  • IMAGING MODULE

    Fluorescent or radioactive molecules can be conjugated to one end of pRNA-3WJ scaffold as imaging module. The near infrared labeling of RNA nanoparticles allows for real time monitoring of bio-distribution in vivo using IVIS imaging system.

The functional Modules can be selected from below with any combination or stoichiometry according to your project requirement:

1. Targeting Ligand: aptamers or chemical ligand
2. Imaging Module: Fluorescent or radiolabeled
3. Therapeutics Module: siRNA, miRNA, anti-miRNA, chemical drugs

Advantages of
RNA Nanoparticles
for Therapy

1) Negative charge disallows nonspecific permeation of negatively charged cell membrane

2) Controlled synthesis provides defined structure and stoichiometry

3) Multi-valency allows combination therapy and simultaneous targeting and detection

4) Targeted delivery allows receptor mediated endocytosis

5) Advantageous size (10 – 40 nm)

6) Extended in vivo half-life (5-12 hr compared to 15-45 min for siRNA)

7) Avoidance of antibody induction (protein-free) allows repeated treatment for chronic diseases.

8) Favorable pharmacokinetic profile in mice:

– Half-life (T1/2) : 5-10 hr compared to 0.25-0.76 hr of siRNA counterpart

– Clearance (Cl): 0.13 l/kg/hr

– Volume of distribution (V(d)): 1.2 l/kg

– Does not induce interferon (IFN) response or cytokine production

– Repeated IV administrations of up to 30 mg/kg do not result in toxicity

9) RNA nanoparticles are classified as chemical drugs rather than biologics. This classification facilitates drug approval.

AFM Image of RNA-3WJ Nanoparticles

RNA Nanoparticles for Cancer Targeting in vivo

Get Industry
Expert Consultation

For Investors

Advantages of RNA Nanoparticles for Therapy
  • -Negative charge disallows nonspecific permeation of negatively charged cell membrane

  • -Controlled synthesis provides defined structure and stoichiometry

  • -Multi-valency allows combination therapy and simultaneous targeting and detection

  • -Targeted delivery allows receptor mediated endocytosis

  • -Advantageous size (10 – 40 nm)

  • -Extended in vivo half-life (5-12 hr compared to 15-45 min for siRNA)

  • -Avoidance of antibody induction (protein-free) allows repeated treatment for chronic diseases

  • - Favorable pharmacokinetic profile in mice:

    • Half-life (T1/2) : 5-10 hr compared to 0.25-0.76 hr of siRNA counterpart;

    • Clearance (Cl): <0.13 l/kg/hr,

    • Volume of distribution (V(d)): 1.2 l/kg;

    • Does not induce interferon (IFN) response or cytokine production;

    • Repeated IV administrations of up to 30 mg/kg do not result in toxicity.

  • - RNA nanoparticles are classified as chemical drugs rather than biologics. This classification facilitates drug approval.

Contact Us